Evidence map›Paper›PMID 26660690›Full record

ArticleJournal of medical systems2016

DRUGS System Improving the Effects of Clinical Pathways: A Systematic Study.

Shan Wang, Xiaohe Zhu, Xian Zhao, Yang Lu, Zhifu Yang, Xiaoliang Qian, Weiwei Li, Lixiazi Ma, Huning Guo, Jingwen Wang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of medical systems, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shan WangDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Xiaohe ZhuDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Xian ZhaoDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Yang LuDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Zhifu YangDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Xiaoliang QianDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Weiwei LiDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Lixiazi MaDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Huning GuoDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
Jingwen WangDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China. wjlbzw@fmmu.edu.cn.
Aidong WenDepartment of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China. adwen-2004@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study is to assess the feasibility of Drugs Rational Usage Guideline System (DRUGS)-supported clinical pathway (CP) for breast carcinoma, cataract, inguinal hernia and 2-diabetes mellitus whether the application of such a system could improve work efficiency, medical safety, and decrease hospital cost. Four kinds of diseases which included 1773 cases (where 901 cases using paper-based clinical pathways and 872 cases using DRUGS-supported clinical pathways) were selected and their demographic and clinical data were collected. The evaluation criteria were length of stay, preoperative length of stay, hospital cost, antibiotics prescribed during hospitalization, unscheduled surgery, complications and prognosis. The median total LOS was 1 to 3 days shorter in the DRUGS-supported CP group as compared to the Paper-based CP group for all types (p < 0.05). Totel hospital cost decreased significantly in the DRUGS-supported CP group than that in Paper-based CP group. About antibiotics prescribed during hospitalization, there were no statistically differences in the time of initial dose of antibiotic and the duration of administration except the choice of antibiotic categories. The proportion of DRUGS-supported clinical pathway conditions where a broad-spectrum antibiotic was prescribed decreased from 63.6 to 34.5 % (p < 0.01) in the Paper-based group. While after the intervention, the differences were statistically not significant in unscheduled surgery, complications and prognosis. In this study, DRUGS-supported clinical pathway for breast carcinoma, cataract, inguinal hernia, 2-diabetes mellitus was smoothly shifted from a paper-based to an electronic system, and confer benefits at the hospital level.

Indexed as

Efficiency, OrganizationalAdultAgedAnti-Bacterial AgentsBreast NeoplasmsCataract ExtractionCritical PathwaysDiabetes Mellitus, Type 2Drug UtilizationFemaleHerniorrhaphyHospital CostsHumansLength of StayMaleMedication Systems, HospitalAnti-Bacterial AgentsClinical pathwayDrugs rational usage guideline systemMedical safetyWork efficiency

Identifiers

PMID26660690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.